Financial Ratios Protagonist Therapeutics, Inc.
Equities
PTGX
US74366E1029
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 81.87 USD | -1.86% |
|
-3.47% | -5.80% |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -16.82 | -23.4 | -27.57 | -19.32 | 28.66 | |||||
Return on Total Capital | -21.08 | -26.6 | -31.27 | -21.01 | 30.87 | |||||
Return On Equity % | -36.79 | -43.32 | -49.41 | -28.59 | 54.39 | |||||
Return on Common Equity | -36.79 | -43.32 | -49.41 | -28.59 | 54.39 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 100 | 100 | 100 | 100 | 100 | |||||
SG&A Margin | 65.1 | 99.41 | 119.4 | 55.82 | 10 | |||||
EBITDA Margin % | -222.6 | -457.04 | -490.35 | -154.46 | 58.39 | |||||
EBITA Margin % | -225.36 | -460.01 | -494.24 | -156.09 | 58.2 | |||||
EBIT Margin % | -225.36 | -460.01 | -494.24 | -156.09 | 58.2 | |||||
Income From Continuing Operations Margin % | -231.07 | -458.94 | -479.26 | -131.59 | 63.34 | |||||
Net Income Margin % | -231.07 | -458.94 | -479.26 | -131.59 | 63.34 | |||||
Net Avail. For Common Margin % | -231.07 | -458.94 | -479.26 | -131.59 | 63.34 | |||||
Normalized Net Income Margin | -140.29 | -286.83 | -299.54 | -82.24 | 40.2 | |||||
Levered Free Cash Flow Margin | -81.79 | -225.13 | -227.12 | -72.18 | 14.99 | |||||
Unlevered Free Cash Flow Margin | -81.04 | -225.13 | -227.12 | -72.18 | 14.99 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.12 | 0.08 | 0.09 | 0.2 | 0.79 | |||||
Fixed Assets Turnover | 4.05 | 4.16 | 4.68 | 17.71 | 58.88 | |||||
Receivables Turnover (Average Receivables) | 6.24 | 13.71 | 33.73 | 11.99 | 4.96 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 7.84 | 7.74 | 7.8 | 16.71 | 12.48 | |||||
Quick Ratio | 7.69 | 7.55 | 7.61 | 16.54 | 12.39 | |||||
Operating Cash Flow to Current Liabilities | -1.8 | -2.45 | -3.47 | -3.3 | 3.89 | |||||
Days Sales Outstanding (Average Receivables) | 58.69 | 26.63 | 10.82 | 30.45 | 73.72 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 2.13 | 1.95 | 1.7 | 0.34 | 1.61 | |||||
Total Debt / Total Capital | 2.09 | 1.92 | 1.67 | 0.34 | 1.58 | |||||
LT Debt/Equity | 1.61 | 1.22 | 0.53 | - | 1.53 | |||||
Long-Term Debt / Total Capital | 1.58 | 1.2 | 0.52 | - | 1.51 | |||||
Total Liabilities / Total Assets | 13.83 | 13.71 | 13.04 | 5.94 | 9.32 | |||||
EBIT / Interest Expense | -107.89 | - | - | - | - | |||||
EBITDA / Interest Expense | -103.75 | - | - | - | - | |||||
(EBITDA - Capex) / Interest Expense | -104.54 | - | - | - | - | |||||
Total Debt / EBITDA | -0.1 | -0.05 | -0.03 | -0.01 | 0.04 | |||||
Net Debt / EBITDA | 4.87 | 2.61 | 1.82 | 3.76 | -2.14 | |||||
Total Debt / (EBITDA - Capex) | -0.1 | -0.05 | -0.03 | -0.01 | 0.04 | |||||
Net Debt / (EBITDA - Capex) | 4.83 | 2.58 | 1.81 | 3.74 | -2.15 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 12.29K | -4.44 | -2.84 | 125.73 | 624.06 | |||||
Gross Profit, 1 Yr. Growth % | 12.29K | -4.44 | -2.84 | 125.73 | 624.06 | |||||
EBITDA, 1 Yr. Growth % | -20.16 | 96.69 | 4.24 | -28.9 | -373.72 | |||||
EBITA, 1 Yr. Growth % | -19.88 | 95.06 | 4.39 | -28.71 | -369.98 | |||||
EBIT, 1 Yr. Growth % | -19.88 | 95.06 | 4.39 | -28.71 | -369.98 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -14.3 | 89.8 | 1.47 | -38.02 | -448.54 | |||||
Net Income, 1 Yr. Growth % | -14.3 | 89.8 | 1.47 | -38.02 | -448.54 | |||||
Normalized Net Income, 1 Yr. Growth % | -17.49 | 95.38 | 1.47 | -38.02 | -453.88 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -35.48 | 40.93 | -4.07 | -46.45 | -404.11 | |||||
Accounts Receivable, 1 Yr. Growth % | -64.09 | -35.45 | -99.36 | 99.9K | 1.55K | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -16.98 | 5.02 | -31.3 | -53.55 | 486.64 | |||||
Total Assets, 1 Yr. Growth % | 109.45 | 7.16 | -28.69 | 44.38 | 108.05 | |||||
Tangible Book Value, 1 Yr. Growth % | 249.66 | 7.3 | -28.14 | 56.15 | 100.58 | |||||
Common Equity, 1 Yr. Growth % | 249.66 | 7.3 | -28.14 | 56.15 | 100.58 | |||||
Cash From Operations, 1 Yr. Growth % | 74.55 | 48.81 | 0.25 | -35.05 | -362.19 | |||||
Capital Expenditures, 1 Yr. Growth % | -51.29 | 133.76 | -27.79 | -23.4 | 122.5 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -35.27 | 163.02 | -1.98 | -28.27 | -250.35 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -35.72 | 167.28 | -1.98 | -28.27 | -250.35 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -3.79 | 988.25 | -3.64 | 48.1 | 304.27 | |||||
Gross Profit, 2 Yr. CAGR % | -3.79 | 988.25 | -3.64 | 48.1 | 304.27 | |||||
EBITDA, 2 Yr. CAGR % | 23.56 | 25.18 | 43.19 | -13.91 | 39.51 | |||||
EBITA, 2 Yr. CAGR % | 23.54 | 25.02 | 42.7 | -13.73 | 38.73 | |||||
EBIT, 2 Yr. CAGR % | 23.54 | 25.02 | 42.7 | -13.73 | 38.73 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 30.36 | 27.54 | 38.77 | -20.7 | 46.97 | |||||
Net Income, 2 Yr. CAGR % | 30.36 | 27.54 | 38.77 | -20.7 | 46.97 | |||||
Normalized Net Income, 2 Yr. CAGR % | 27.19 | 26.97 | 40.8 | -20.7 | 48.1 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 5.12 | -4.65 | 16.27 | -28.36 | 27.55 | |||||
Accounts Receivable, 2 Yr. CAGR % | -27.28 | -51.85 | -93.58 | 152.7 | 12.75K | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 172.89 | -6.62 | -15.06 | -43.51 | 65.08 | |||||
Total Assets, 2 Yr. CAGR % | 52.53 | 49.81 | -12.59 | 1.46 | 73.31 | |||||
Tangible Book Value, 2 Yr. CAGR % | 57.64 | 93.7 | -12.19 | 5.93 | 76.98 | |||||
Common Equity, 2 Yr. CAGR % | 57.64 | 93.7 | -12.19 | 5.93 | 76.98 | |||||
Cash From Operations, 2 Yr. CAGR % | 20.47 | 61.17 | 22.14 | -19.31 | 30.5 | |||||
Capital Expenditures, 2 Yr. CAGR % | -1.56 | 6.7 | 29.92 | -25.63 | 30.55 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -21.04 | 30.48 | 60.57 | -16.15 | 3.85 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -21.4 | 30.68 | 61.86 | -16.15 | 3.85 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 12.58 | -4 | 386.39 | 27.97 | 151.35 | |||||
Gross Profit, 3 Yr. CAGR % | 12.58 | -4 | 386.39 | 27.97 | 151.35 | |||||
EBITDA, 3 Yr. CAGR % | 19.34 | 44.15 | 17.77 | 13.39 | 26.59 | |||||
EBITA, 3 Yr. CAGR % | 19.4 | 43.86 | 17.72 | 13.23 | 26.18 | |||||
EBIT, 3 Yr. CAGR % | 19.4 | 43.86 | 17.72 | 13.23 | 26.18 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 21.42 | 47.75 | 18.18 | 6.08 | 29.9 | |||||
Net Income, 3 Yr. CAGR % | 21.42 | 47.75 | 18.18 | 6.08 | 29.9 | |||||
Normalized Net Income, 3 Yr. CAGR % | 20.25 | 46.75 | 17.83 | 7.11 | 30.56 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -2.71 | 15.91 | -4.45 | -10.24 | 15.99 | |||||
Accounts Receivable, 3 Yr. CAGR % | 10.13 | -30.11 | -88.6 | 60.34 | 372.31 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 93.94 | 98.5 | -15.7 | -30.54 | 23.25 | |||||
Total Assets, 3 Yr. CAGR % | 25.61 | 35.59 | 16.97 | 3.33 | 28.9 | |||||
Tangible Book Value, 3 Yr. CAGR % | 32.34 | 38.67 | 39.18 | 6.39 | 31.05 | |||||
Common Equity, 3 Yr. CAGR % | 32.34 | 38.67 | 39.18 | 6.39 | 31.05 | |||||
Cash From Operations, 3 Yr. CAGR % | 165.52 | 29.26 | 37.58 | -1.04 | 19.52 | |||||
Capital Expenditures, 3 Yr. CAGR % | -10.91 | 31.34 | -6.32 | 8.94 | 7.16 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 15.71 | 17.92 | 18.62 | 22.75 | 1.87 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 15.36 | 17.92 | 18.73 | 23.41 | 1.87 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | - | - | 5.79 | 14.17 | 351.71 | |||||
Gross Profit, 5 Yr. CAGR % | - | - | 5.79 | 14.17 | 351.71 | |||||
EBITDA, 5 Yr. CAGR % | 34.37 | 31.05 | 28.3 | 17.29 | 26.03 | |||||
EBITA, 5 Yr. CAGR % | 34.25 | 30.96 | 28.23 | 17.25 | 25.72 | |||||
EBIT, 5 Yr. CAGR % | 34.25 | 30.96 | 28.23 | 17.25 | 25.72 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 34.81 | 27.56 | 28.08 | 15.19 | 28.95 | |||||
Net Income, 5 Yr. CAGR % | 34.81 | 27.56 | 28.08 | 15.19 | 28.95 | |||||
Normalized Net Income, 5 Yr. CAGR % | 34.03 | 27.56 | 28.08 | 14.73 | 29.11 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -49.63 | -14.13 | 4.48 | -4.38 | 7.25 | |||||
Accounts Receivable, 5 Yr. CAGR % | - | - | -64.67 | 16.87 | 89.48 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 60.13 | 64.33 | 39.39 | 20.07 | 10.3 | |||||
Total Assets, 5 Yr. CAGR % | 85.32 | 29.9 | 8.65 | 20.74 | 36.89 | |||||
Tangible Book Value, 5 Yr. CAGR % | 59.13 | 27.93 | 12.32 | 24.51 | 53.22 | |||||
Common Equity, 5 Yr. CAGR % | 59.13 | 27.93 | 12.32 | 24.51 | 53.22 | |||||
Cash From Operations, 5 Yr. CAGR % | 38.19 | 29.19 | 94.63 | 7.06 | 34.7 | |||||
Capital Expenditures, 5 Yr. CAGR % | 3.37 | 25.98 | 3.6 | 4.62 | 6.98 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 20.5 | 27.37 | 31.91 | 2.89 | 12.47 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 20.28 | 27.37 | 31.91 | 2.89 | 12.54 |
- Stock Market
- Equities
- PTGX Stock
- Financials Protagonist Therapeutics, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















